Dr. Bruce Morimoto has been appointed executive director of Applied Translational Medicine at Celerion. Dr. Morimoto is responsible for developing and implementing strategies for patient populations in early clinical research and clinical pharmacology studies. Dr. Morimoto will also lead the external studies management and clinical monitoring services teams.
Dr. Morimoto has more than 20 years of experience in the pharmaceutical and biotechnology, and CRO industries. He joins the company from Allon Therapeutics, where he served as vice president of drug development. His focus was to manage Allon’s neurodegeneration and dementia therapeutic programs including preclinical, manufacturing and clinical development. Dr. Morimoto also held positions at MDS Pharma Services, Neuromed Technologies, Phoenix International Life Sciences, and Amur Pharmaceuticals.
“We are very pleased to have Bruce join the Drug Development Services team at Celerion,” said Susan Thornton Ph.D., president and chief executive officer of Celerion. “His in-depth knowledge of drug development as well as focus on Applied Translational Medicine from both the client and CRO perspective will be a great asset to our organization.”